Search
Hematology and oncology, pacemakers for EU HTA
EHA’s Martin Kaiser, right, addressing his fellow panelists. Left to right: Brian Cuffel (Bayer), Caroline Pothet (EMA), Roisin Adams (HTA CG), Bernhard Wörmann (DGHO) and Elisabeth de Vries (ESMO).
Read moreSubstances of Human Origin (SoHO) legislation
EHA’s involvementEHA has been involved in both the evaluation and subsequent revision of the EU legislation on human blood and blood components. The evaluation of these rules, which dated back to 2002, began in 2016.
Read moreRegistration & accommodation
Register here
Individual registrationIn-person registration fee includes:
Access to the scientific and educational sessions of the meeting
Networking opportunities to speak with the faculty during breaks and the welcome reception
Coffee/tea breaks and lunches on April 25 and 26
Access to the poster sessions and…
Urgent action needed to avoid widespread shortage of in-vitro diagnostic tests
In a new statement, BioMed Alliance highlights its increasing concern about the availability of In Vitro Diagnostic (IVD) testing devices in Europe.
Read moreEHA-LSHBT Virtual Hematology Updates
EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies.
Read moreEHA-SRH-SHTRM Balkan Hematology Tutorial 2023
EHA is joining forces with the Societatea Românã de Hematologie (SRH) and Scientific and Practical Society of Hematologists and Transfusiologists from the Republic of Moldova (SHTRM) to organize the EHA-SRH-SHRTM Balkan Hematology Tutorial.
Read moreSustainability
Actions we're taking to reduce the environmental impact of our flagship event: the EHA Congress.
Read moreInternational CML adherence survey launched
The drivers behind non-adherence, a highly prevalent problem in oral cancer treatments but also in many other diseases like diabetes, are not well understood to date.
Read moreCAR NK-cells project, February 2025 update
A project update from Dr Ciprian Tomuleasa. We successfully designed and tested in vitro CAR T and CAR NK cells, transfected with the iCas9 suicide trigger.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- »